Does PSA level affect the choice of prostate puncture methods among MRI-ultrasound fusion targeted biopsy, transrectal ultrasound systematic biopsy or the combination of both?

• Published in: British journal of radiology 2021-07, Vol.94 (1123), p.20210312-20210312
• Main Authors: Liu, Yunyun, Dong, Lin, Xiang, Lihua, Zhou, Boyang, Wang, Hanxiang, Zhang, Ying, Xu, Guang, Wu, Jian, Wang, Shuai, Zhang, Yifeng, Xu, Huixiong
• Format: Article
• Language: English
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr.20210312

To explore whether prostate-specific antigen (PSA) affects the choice of prostate puncture methods by comparing MRI-ultrasound fusion targeted biopsy (MRI-TBx) with transrectal ultrasound systematic biopsy (TRUS-SBx) in the detection of prostate cancer (PCa), clinically significant prostate cancer (csPCa) and non-clinically significant prostate cancer (nsPCa) in different PSA groups (20.0 ng ml ). A total of 190 patients with 215 lesions who underwent both MRI-TBx and TRUS-SBx were included in this retrospective study. PSA was measured pre-operatively and stratified to three levels. The detection rates of PCa, csPCa and nsPCa through different methods (MRI-TBx, TRUS-SBx, or MRI-TBx +TRUS SBx) were compared with stratification by PSA. Among the 190 patients, the histopathological results revealed PCa in 126 cases, including 119 csPCa. In PSA 20.0 ng ml , MRI-TBx had a higher csPCa rate than TRUS-SBx with no statistical significance noted ( = 0.600). MRI-TBx combined with TRUS-SBx could be suitable as a standard detection approach for csPCa in patients with PSA 10.0-20.0 ng ml . As for PSA >20.0 and